Cytosorbents (NASDAQ:CTSO) Earns Buy Rating from D. Boral Capital

by · The Cerbat Gem

Cytosorbents (NASDAQ:CTSO – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the medical research company’s stock.

Other analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a report on Tuesday, October 14th. HC Wainwright decreased their price objective on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a report on Friday, November 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.38.

Check Out Our Latest Research Report on Cytosorbents

Cytosorbents Stock Up 3.3%

Shares of Cytosorbents stock traded up $0.02 during trading hours on Tuesday, hitting $0.65. The company had a trading volume of 53,690 shares, compared to its average volume of 160,718. The company’s 50-day moving average is $0.78 and its two-hundred day moving average is $0.93. Cytosorbents has a twelve month low of $0.60 and a twelve month high of $1.61. The company has a debt-to-equity ratio of 1.61, a current ratio of 2.11 and a quick ratio of 1.71. The company has a market cap of $40.63 million, a P/E ratio of -3.59 and a beta of 1.28.

Cytosorbents (NASDAQ:CTSO – Get Free Report) last announced its quarterly earnings results on Friday, January 3rd. The medical research company reported ($0.08) EPS for the quarter. Cytosorbents had a negative return on equity of 101.14% and a negative net margin of 27.77%.The company had revenue of $8.61 million for the quarter. Analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Cytosorbents

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC increased its stake in shares of Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock worth $61,000 after acquiring an additional 36,790 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Cytosorbents during the 3rd quarter worth approximately $105,000. CIBC Bancorp USA Inc. purchased a new position in shares of Cytosorbents during the 3rd quarter worth approximately $161,000. Finally, CM Management LLC lifted its holdings in shares of Cytosorbents by 3.1% in the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after buying an additional 38,128 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

(Get Free Report)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Further Reading